|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 安德森博士癌症中心完全腹腔镜下广泛子宫根治术及淋巴结切除术经验显示文摘Objective.:To retrospectively evaluate the feasibility and morbidity of total laparoscopic radical hysterectomy and lymphadenectomy. Methods.:We performed a retrospective review of all patients who underwent a total laparoscopic radical hysterectomy at our institution between May 2004 and August 2005. Data collected included age,body mass index,stage,histopathologic subtype,tumor grade,estimated blood loss,perioperative blood transfusions,number and status of lymph nodes obtained,status of surgical margins,length of hospital stay,time to resumption of normal bladder function,intraoperative and postoperative complications,and disease-free interval. Results.:Twenty patients underwent total laparoscopic radical hysterectomy during the study period. None of the surgeries required conversion to laparotomy. The median patient age was 41.5 years (range,25-76). Eighteen patients had cervix cancer (5 stage IA2 and 13 stage IB1),and 2 had endometrial cancer (1 stage IB and 1 stage IIIA). Among those with cervix cancer,12 had adenocarcinoma,4 squamous cell carcinoma,and 2 adenosquamous carcinoma. The median weight was 70 kg (range,49-112). The median number of resected pelvic lymph nodes was 13 (range,9-26). One patient had nodal disease. The surgical margins were free of disease in all cases. The median blood loss was 200 ml (range,25-700 ml). Only 1 patient required an intraoperative blood transfusion (1 U packed red blood cells). The median length of hospital stay was 1 day (range,1-5). There were 3 short-term complications-unintentional cystotomy,pulmonary embolus,and pneumomediastinum with subcutaneous emphysema. There were 2 long-term complications-vaginal eviscerations and a lymphocyst. The median time to resumption of normal bladder function was 16 days (range,13-29). The median follow-up time was 8 months range (1-16). All patients remain free of disease at the time of this report. Conclusions.:Total laparoscopic radical hysterectomy can be performed safely with minimal blood loss and postoperative morbidity,and patients undergoing this proceduremay be discharged after an overnight stay in the hospital. | Ramirez P.T. Slomovitz B.M. Soliman P.T. 李欢 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，12： | 2 |
| 2 | 同时发生的原发性子宫内膜癌与卵巢癌:84例单中心病例回顾 | Soliman P.T. Slomovitz B.M. Broaddus R.R. K.H. Lu 蔡国青 | 2005 | 世界核心医学期刊文摘(妇产科学分册)2005，0，1： | 0 |
| 3 | 孕酮治疗后子宫内膜增生进展为子宫内膜腺癌显示文摘Background. Conservative treatment with progestins is a reasonable treatment option for endometrial complex atypical hyperplasia and, in the experimental setting, for some women with grade 1 endometrial endometrioid adenocarcinoma. The risk of progression to a high-stage endometrial cancer is quite low, with only two previously reported cases in the English literature. Case. A 40-year-old woman with endometrial complex atypical hyperplasia diagnosed by dilatation and curettage was managed conservatively with progestin therapy (initially, megesterol acetate; then, a combination oral contraceptive). More than 2 years after her original diagnosis, she developed endometrial endometrioid adenocarcinoma,FIGO grade 2, with lymph node metastasis. The tumor was microsatellite instability-high due to methylation of MLH1 and loss of MLH1 protein. Conclusion. Currently, there are no good criteria for predicting which patients with complex atypical hyperplasia/grade 1 endometrioid adenocarcinoma will optimally respond to progestin therapy. There is some evidence that endometrial complex hyperplasia demonstrating loss of MLH1 protein by immunohistochemistry is strongly related to subsequent or concurrent endometrial cancer, especially tumors of higher grade and stage. In a woman with a biopsy diagnosis of endometrial hyperplasia, evaluation of MLH1 protein status by immunohistochemistry may provide useful information when medical management is being considered. | Rubatt J.M. Slomovitz B.M. Burke T.W. Broaddus R.R. 张旸 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，3： | 0 |
| 4 | 服用它莫西芬是否影响发生子宫内膜癌的乳腺癌患者的预后 | Slomovitz B.M. Ramirez P.T. 张丽娟 | 2005 | 世界核心医学期刊文摘(妇产科学分册)2005，0，9： | 0 |
| 5 | 1例宫颈癌患者阴道局部应用对氨基苯磺酰胺乳膏致高铁血红蛋白血症 | Bristol I. Brown J. Slomovitz B.M. P.J. Eifel 李奎 | 2005 | 世界核心医学期刊文摘(妇产科学分册)2005，0，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员